Evidence map›Paper›PMID 37081044›Full record

ReviewProstate cancer and prostatic diseases2024

Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: A review of Aquablation, Rezum, and transperineal laser prostate ablation.

David-Dan Nguyen, Tiange Li, Roseanne Ferreira, Mohamad Baker Berjaoui, Anna-Lisa V Nguyen, Bilal Chughtai, Kevin C Zorn, Naeem Bhojani, Dean Elterman

Abstract readReview
PubMed Publisher
In one paragraph

Review in Prostate cancer and prostatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

David-Dan Nguyen *Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Tiange Li *Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-9420-4933
Roseanne FerreiraDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Mohamad Baker BerjaouiDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Anna-Lisa V NguyenSchulich School of Medicine and Dentistry, Western University, London, ON, Canada.ORCID 0000-0002-7402-3438
Bilal ChughtaiDepartment of Urology, Weill Cornell Medical College, New York, NY, USA.
Kevin C ZornDivision of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada.
Naeem BhojaniDivision of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada.
Dean EltermanDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. dean.elterman@uhn.ca.ORCID 0000-0003-1507-7783

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBenign prostatic hyperplasia (BPH) is one of the most common diseases affecting men and can present with bothersome lower urinary tract symptoms (LUTS). Historically, transurethral resection of the prostate (TURP) has been considered the gold standard in the treatment of LUTS due to BPH. However, TURP and other traditional options for the surgical management of LUTS secondary to BPH are associated with high rates of sexual dysfunction. In the past decade, several novel technologies, including Aquablation therapy, convective water vapor therapy (Rezum), and transperineal prostate laser ablation (TPLA), have demonstrated promising evidence to be safe and effective while preserving sexual function.

methodsIn this review, we discuss three ablative minimally invasive surgeries: Aquablation, Rezum, and TPLA. We review their techniques, safety, as well as perioperative and functional outcomes. We go into further detail regarding sexual function after these ablative minimally invasive surgical therapies.

resultsAquablation is a surgeon-guided, robot-executed, heat-free ablative waterjet procedure with sustained functional outcomes at 5 years while having no effect on sexual activity. Rezum is an innovative office-based, minimally invasive surgical option for BPH that delivers convective water vapor energy into prostate adenoma to ablate obstructing tissue. Rezum leads to significant improvements in Qmax, IPSS while preserving sexual function. TPLA is another office-based technology which uses a diode laser source to produce thermoablation. It leads to improvement in Qmax, IPSS, and QoL while preserving ejaculatory function.

conclusionsOverall, ablative minimally invasive surgical therapies have demonstrated excellent safety and efficacy profiles while preserving sexual function. These modalities should be discussed with patients to ensure informed and shared decision-making. Ablative minimally invasive surgical therapies may be particularly interesting to patients who value the preservation of their sexual function.

Indexed as

Laser TherapyLower Urinary Tract SymptomsProstatic HyperplasiaProstatic NeoplasmsTransurethral Resection of ProstateHumansMaleMinimally Invasive Surgical ProceduresProstateQuality of LifeSteamTreatment OutcomeSteam

Identifiers

PMID37081044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.